---
title: "Eligible patients | Kisqali®"
description: "KISQALI is approved for a broad range of HR+/HER2- early breast cancer patients, including node-negative, node-positive, and high-risk subgroups."
canonical_url: "https://www.kisqali.com/early-breast-cancer/eligible-patients"
meta:
  "og:description": "KISQALI is approved for a broad range of HR+/HER2- early breast cancer patients, including node-negative, node-positive, and high-risk subgroups."
  "og:title": "Eligible patients"
---

### **KISQALI: approved in the broadest \* population including all N+ and high-risk N0 patients **<sup>(1-4)</sup>

Patients with HR+/HER2– EBC: <sup>(1,3)</sup>

**High-risk node negative**

**N0, T2**

**Grade 2 with high-risk features\* **  
**Grade 3 **

**N0, T3-4**

**ALL PATIENTS **

**All node positive**

**N1**

**ALL PATIENTS **

**N2-3**

**ALL PATIENTS **

\* Of all approved CDK4/6i. <sup>(1-4)</sup>  
  
<sup>‡</sup> Grade 3 or grade 2 with additional risk factors, such as Ki-67 score ≥20% or defined as an Oncotype DX Breast Recurrence Score of ≥26, or Prosigna/PAM50, MammaPrint, or EndoPredict EPclin high-risk scores. <sup>(3)</sup>

## Sitemap

See the full [sitemap](/sitemap.md) for all pages.